There are currently 1093 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Facility, Rochester, Minnesota
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT04633239
Recruiting
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma
Register for Updates
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
NCT04707885
Recruiting
The current study is a randomized multi-center clinical trial that investigates the role an intraoperative hearing monitoring system (electrocochleography) has on helping to save residual hearing in patients undergoing cochlear implantation (CI).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
08/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hearing Loss, Sensorineural, Hearing Loss, Hearing Loss, Bilateral
Register for Updates
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04786574
Recruiting
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 4 weeks and 12 weeks
Trial Updated:
08/06/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Register for Updates
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499
Recruiting
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/06/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
NCT06465316
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056
Recruiting
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during res... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Migraine
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukemia
Register for Updates
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232
Recruiting
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: Local Site #840005, Rochester, Minnesota
Conditions: Recurrent Pericarditis
Register for Updates
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Breast Cancer
Register for Updates
Augmented Reality Real-Time Guidance for MRI-Guided Interventions
NCT07120906
Recruiting
The purpose of this research is to evaluate the safety and feasibility of using a needle guidance system (LUMENA) create by CLEAR GUIDE MEDICAL for needle placement for biopsy or liver tumor ablation procedures.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Liver
Register for Updates